Aerska is developing RNA interference (RNAi) medicines for brain diseases, aiming to silence genes that cause neurodegeneration.

Its platform combines brain shuttle technology, which allows oligonucleotides to cross the blood-brain barrier, with precision medicine approaches to achieve potent and lasting gene knockdown in the central nervous system. Initially focused on Alzheimer’s and Parkinson’s disease, Aerska is advancing a new generation of targeted RNAi therapies that translate molecular innovation into treatments for complex neurological disorders.

Aerska’s mission statement states:

“By silencing the genes that cause harm, we aim to preserve minds, protect memories, and enable our loved ones to live healthier, longer lives.”